Table 1.
N | % | |
---|---|---|
No. of patients | 31 | |
Gender | ||
Male | 15 | 48 |
Female | 16 | 52 |
Race | ||
Caucasian | 30 | 97 |
Asian | 1 | 3 |
Median age (years) | 63 | |
Range | 37–77 | |
Stage | ||
Metastatic | 29 | 94 |
Locally advanced | 2 | 6 |
WHO performance status | ||
0 | 16 | 52 |
1 | 11 | 35 |
2 | 4 | 13 |
Histology | ||
Adenocarcinoma | 30 | 97 |
Acinar cell carcinoma | 1 | 3 |
Prior therapy | ||
First line | 15 | 48 |
Neoadjuvant CRT | 1 | 3 |
Adjuvant gemcitabine | 1 | 3 |
Second line | 16 | 52 |
Adjuvant gemcitabinea | 5 | 16 |
Palliative | 11 | 35 |
WHO World Health Organization, CRT chemoradiotherapy
aProgression during or within 6 months after adjuvant treatment